Therefore, post-COVID-19 patients should be monitored for liver damage (AST and ALT), endovascular thrombotic processes (D-dimer), persisting pulmonary symptoms (CAT, Barthel, DLCO, SpO2, PaO2, FEV1, FVC, FEV1/FVC, FEV1%, FVC%), and physical impairment (6MWD). This evidence concerns the gene GPT and COVID-19.